Teva image

Teva and Heptares enter $400m agreement for small-molecule migraine treatment

pharmafile | November 25, 2015 | News story | Research and Development Heptares, Teva, collaboration, migraine 

Teva Pharmaceuticals and Heptares Therapeutics have signed a licensing and drug-discovery agreement for Teva to gain exclusive global rights to develop, manufacture and commercialise new migraine treatments.

Israeli-based Teva and Heptares, which is a wholly owned subsidiary of Sosei Group Corporation, struck the deal for novel, small-molecule calcitonin gene-related peptide (CGRP) antagonists discovered by Heptares for the treatment of migraine. 

Under the terms of the agreement, Heptares will receive an upfront payment of $10 million, research funding, and is eligible to receive additional research, development and commercialization milestone payments of up to $400 million. In addition, Heptares will be eligible to receive royalties on net sales of products resulting from the alliance. 

Michael Hayden, president of global R&D and chief scientific officer at Teva says: “We are delighted to begin this partnership with Heptares, which through its industry-leading, structure-based design approach has generated novel CGRP antagonists with significant promise for treating migraine.” 

“CGRP antagonism represents an exciting opportunity to treat migraine. We believe small-molecule CGRP antagonists offer further opportunities that are highly complementary to our promising candidate, TEV-48125, an anti-CGRP antibody.” 

Malcolm Weir, chief executive officer of Heptares says: “This agreement is an exciting development for our CGRP antagonist program. Teva brings world-leading clinical and commercial expertise in migraine to advance this program based on differentiated small-molecule CGRP antagonists discovered using our novel structure-based drug design technologies. The commitment Teva is making allows us to expand this promising program.” 

Yasmita Kumar

Related Content

milad-fakurian-58z17lnvs4u-unsplash_2

Autifony announces global license and collaboration agreement with Jazz Pharmaceuticals

Autifony Therapeutics has announced that it has entered an exclusive global licensing agreement with Jazz …

Halozyme and Acumen Pharmaceuticals enter collaboration for Alzheimer’s treatment

Halozyme Therapeutics has announced a global collaboration and non-exclusive license with Acumen Pharmaceuticals, providing Acumen …

louis-reed-pwckf7l4-no-unsplash_5

Sanofi and Teva partner for development of inflammatory bowel disease treatment

Sanofi and Teva Pharmaceuticals have announced that they will collaborate for the co-development and co-commercialisation …

Latest content